BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 8976821)

  • 1. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol).
    Schuchter LM
    Eur J Cancer; 1996; 32A Suppl 4():S40-2. PubMed ID: 8976821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V; Giles FJ
    Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
    Capizzi RL; Oster W
    Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
    Treskes M; van der Vijgh WJ
    Cancer Chemother Pharmacol; 1993; 33(2):93-106. PubMed ID: 8261581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
    Capizzi RL
    Semin Oncol; 1994 Oct; 21(5 Suppl 11):8-15. PubMed ID: 7973776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amifostine: chemotherapeutic and radiotherapeutic protective effects.
    Santini V
    Expert Opin Pharmacother; 2001 Mar; 2(3):479-89. PubMed ID: 11336600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM; Mallmann PK
    Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of the cytoprotectant amifostine.
    Lindemann K
    Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amifostine for protection from antineoplastic drug toxicity.
    Foster-Nora JA; Siden R
    Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
    Sastry J; Kellie SJ
    Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
    Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
    Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurologic protection by amifostine.
    DiPaola RS; Schuchter L
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):82-8. PubMed ID: 10348265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
    Links M; Lewis C
    Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity.
    Duval M; Daniel SJ
    J Otolaryngol Head Neck Surg; 2012 Oct; 41(5):309-15. PubMed ID: 23092832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
    van der Vijgh WJ; Korst AE
    Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Amifostine (ethyol) in the adjunctive treatment of children with acute lymphoblastic leukemia].
    Matysiak M; Stańczak E; Wójtowicz A
    Wiad Lek; 1998; 51 Suppl 4():210-4. PubMed ID: 10731970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The need for cytoprotection.
    Bukowski RM
    Eur J Cancer; 1996; 32A Suppl 4():S2-4. PubMed ID: 8976815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effects of amifostine (Ethyol) in patients treated with carboplatin.
    Budd GT; Ganapathi R; Bukowski RM; Murthy S
    Eur J Cancer; 1996; 32A Suppl 4():S43-5. PubMed ID: 8976822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.